Search

Roche Holding AG

Închisă

SectorSănătate

283.2 -0.07

Rezumat

Modificarea prețului

24h

Curent

Minim

279.6

Maxim

286

Indicatori cheie

By Trading Economics

Venit

1.7B

3.7B

Vânzări

-15B

16B

P/E

Medie Sector

25.123

37.461

Randament dividend

3.28

Marjă de profit

23.266

Angajați

103,249

EBITDA

547M

6.5B

Dividende

By Dow Jones

Randament dividend

Medie Sector

3.28%

2.33%

Statistici piață

By TradingEconomics

Capitalizare de piață

22B

227B

Deschiderea anterioară

283.27

Închiderea anterioară

283.2

Roche Holding AG Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

23 oct. 2025, 09:32 UTC

Câștiguri

Roche Raises Full-Year Earnings Outlook as U.S. Drug-Pricing Talks Continue -- Update

23 oct. 2025, 05:54 UTC

Câștiguri

Roche Raises Full-Year Earnings Outlook

1 oct. 2025, 08:54 UTC

Principalele dinamici ale pieței

Pharma Stocks in Europe Jump After White House Unveils Drug-Buying Site

18 sept. 2025, 14:01 UTC

Achiziții, Fuziuni, Preluări

Roche to Buy Maker of Fatty Liver Treatment 89bio for Up to $3.5 Billion -- 2nd Update

18 sept. 2025, 10:05 UTC

Principalele dinamici ale pieței
Achiziții, Fuziuni, Preluări

89bio Shares Soar Premarket on Takeover by Roche

18 sept. 2025, 10:04 UTC

Achiziții, Fuziuni, Preluări

Roche to Buy Maker of Fatty Liver Treatment 89bio for Up to $3.5 Billion -- Update

18 sept. 2025, 05:37 UTC

Achiziții, Fuziuni, Preluări

Roche to Buy 89bio for Up to $3.5 Billion

23 oct. 2025, 09:19 UTC

Market Talk
Câștiguri

Roche's Sales Slow, But Drug Pipeline Could Support Long-Term Growth -- Market Talk

23 oct. 2025, 09:11 UTC

Market Talk
Câștiguri

Roche Sales Miss Driven by Underperformance of Key Drugs -- Market Talk

23 oct. 2025, 05:09 UTC

Câștiguri

Roche 3Q Sales Up 6% At CER

23 oct. 2025, 05:07 UTC

Câștiguri

Roche 3Q Sales CHF14.92B

23 oct. 2025, 05:07 UTC

Câștiguri

Analysts Had Seen 3Q Sales At CHF15.17B

23 oct. 2025, 05:07 UTC

Câștiguri

Roche See Core Earnings Per Share Growth In High-Single to Low-Double-Digit Range At CER

23 oct. 2025, 05:05 UTC

Câștiguri

Roche Expects An Increase In Group Sales In Mid-Single-Digit Range At CER

23 oct. 2025, 05:04 UTC

Câștiguri

Roche: Group Sales Up 7% At Constant Exchange Rates In First Nine Months

23 oct. 2025, 05:02 UTC

Câștiguri

Roche Had Seen High-Single-Digit 2025 Core Earnings Per Share Growth at CER

23 oct. 2025, 05:02 UTC

Câștiguri

Roche Had Seen Mid-Single-Digit 2025 Sales Growth At Constant Exchange Rates

23 oct. 2025, 05:02 UTC

Câștiguri

Roche 9-Mos CH45.9B

23 oct. 2025, 05:01 UTC

Câștiguri

Roche Raises 2025 View

1 oct. 2025, 20:33 UTC

Achiziții, Fuziuni, Preluări

Roche Begins Tender Offer for 89bio Pursuant to Previously Announced Merger Agreement

1 oct. 2025, 09:05 UTC

Acțiuni populare

Stocks to Watch Wednesday: Nike, Lithium Americas, Arm, Occidental -- WSJ

18 sept. 2025, 14:12 UTC

Achiziții, Fuziuni, Preluări

89bio Stock Soars 86%. Why Roche Is Buying the Biopharma Company for $3.5 Billion. -- Barrons.com

18 sept. 2025, 07:37 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Roche's 89bio Acquisition Gives Its Drug Pipeline Potential Blockbuster -- Market Talk

18 sept. 2025, 05:09 UTC

Achiziții, Fuziuni, Preluări

89bio Says Deal Reflects Potential of Pegozafermin Drug Candidate

18 sept. 2025, 05:06 UTC

Achiziții, Fuziuni, Preluări

Roche: Deal Is Expected to Close in 4Q

18 sept. 2025, 05:06 UTC

Achiziții, Fuziuni, Preluări

Roche: Deal Enhanc Portfolio in Cardiovascular, Renal, Metabolic Diseases

18 sept. 2025, 05:05 UTC

Achiziții, Fuziuni, Preluări

Roche: MASH Is One of Most Prevalent Comorbidities of Obesity

18 sept. 2025, 05:05 UTC

Achiziții, Fuziuni, Preluări

Roche: 89bio Developing Potential Treatment for Metabolic Dysfunction-Associated Steatohepatitis

18 sept. 2025, 05:04 UTC

Achiziții, Fuziuni, Preluări

Roche to Buy 89bio for $14.50 a Share in Cash, Contingent Value Right of Up to $6 a Share

18 sept. 2025, 05:03 UTC

Achiziții, Fuziuni, Preluări

Roche: Total Deal Value Is Up to $3.5B

Roche Holding AG Așteptări

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Roche Holding AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. It has strategic discovery collaboration with Flare Therapeutics Inc. proteomic and mass spectrometry platform and expertise to discover novel small molecules aimed at transcription factor targets in oncology. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.
help-icon Live chat